• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Introduction to 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid (CAS No. 693798-28-6)

4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 693798-28-6, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This benzoic acid derivative features a unique structural configuration, incorporating both benzyloxy and ethoxy substituents alongside a chloro group, which endows it with distinct chemical and pharmacological properties. The compound's molecular structure, characterized by its aromatic core and functional groups, makes it a promising candidate for further exploration in drug discovery and therapeutic applications.

The synthesis of 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid involves meticulous chemical transformations that highlight the compound's synthetic accessibility while maintaining high purity standards. The presence of the chloro group at the 3-position enhances its reactivity, allowing for further derivatization into more complex molecules. This feature is particularly valuable in medicinal chemistry, where structural modifications can fine-tune biological activity and pharmacokinetic profiles.

In recent years, there has been growing interest in benzoic acid derivatives due to their diverse biological activities. Studies have demonstrated that compounds with similar structural motifs exhibit potential in modulating various biological pathways, including inflammatory responses, enzyme inhibition, and cellular signaling. The specific arrangement of substituents in 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid may contribute to its unique interaction with biological targets, making it a subject of intense research.

One of the most compelling aspects of 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid is its potential as a scaffold for developing novel therapeutic agents. Researchers have been exploring its utility in designing molecules that can interact with specific enzymes or receptors involved in disease pathways. For instance, preliminary studies suggest that derivatives of this compound may exhibit inhibitory effects on certain kinases or transcription factors, which are implicated in conditions such as cancer and neurodegenerative disorders.

The benzyloxy group in the molecule contributes to its solubility and stability, which are critical factors in drug formulation and delivery. Additionally, the ethoxy substituent at the 5-position introduces another layer of functional diversity, enabling further chemical modifications to optimize pharmacological properties. These features make 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid a versatile building block for medicinal chemists.

Recent advancements in computational chemistry have accelerated the process of identifying promising drug candidates. Molecular modeling studies have been employed to predict the binding affinity of 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid to various biological targets. These simulations have provided valuable insights into its potential mechanisms of action and have guided experimental design for further validation.

In clinical research settings, 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid has been investigated for its potential therapeutic benefits. While still largely in the preclinical phase, early findings indicate that this compound may possess anti-inflammatory and antioxidant properties. These effects are particularly relevant given the increasing recognition of oxidative stress and inflammation as key contributors to numerous diseases.

The compound's structural similarity to known pharmaceuticals also makes it an attractive candidate for structure-based drug design. By leveraging existing knowledge about how related compounds interact with biological systems, researchers can more efficiently develop derivatives with enhanced efficacy and reduced side effects. This approach aligns with the broader trend toward rational drug design, which aims to minimize trial-and-error experimentation and accelerate the discovery process.

From a synthetic chemistry perspective, 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid exemplifies the importance of strategic functional group placement. The interplay between electronic effects and steric hindrance influenced by the benzyloxy, chloro, and ethoxy groups determines its reactivity and compatibility with various chemical transformations. Understanding these relationships is crucial for optimizing synthetic routes and achieving high yields of pure product.

The future prospects for 4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid are promising, with ongoing research expected to uncover new applications and refine its therapeutic potential. As computational methods continue to evolve, so too will our ability to predict and validate the biological activity of this compound. Collaborative efforts between chemists, biologists, and clinicians will be essential in translating laboratory findings into tangible medical benefits.

In conclusion,4-(benzyloxy)-3-chloro-5-ethoxybenzoic acid (CAS No. 693798-28-6) represents a significant advancement in pharmaceutical chemistry. Its unique structural features offer a rich foundation for developing novel therapeutics targeting various diseases. With continued investigation and innovation, this compound holds great promise for improving human health through targeted molecular interventions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)